Aldeyra Therapeutics Inc

Research Aldeyra Therapeutics Inc (ALDX) on Bullrun: market cap USD 123.66M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerALDX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 123.66M
• Financial periodFY2025
• Net income-USD 33.85M

Valuation Snapshot

latest market cap is USD 123.66M.

About Aldeyra Therapeutics Inc

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.

Frequently asked questions

What is Aldeyra Therapeutics Inc's market cap?

Aldeyra Therapeutics Inc's market capitalization is USD 123.66M.

What does Aldeyra Therapeutics Inc do?

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.